The Hepatitis C Drugs Market has seen significant growth in recent years due to advancements in treatment options. Hepatitis C is a viral infection that causes liver inflammation and can lead to liver cirrhosis and liver cancer. The market is driven by factors such as increasing prevalence of Hepatitis C, improving healthcare infrastructure, and the launch of new and more effective drugs. In addition, increasing government support for the treatment of Hepatitis C and increasing investment by major pharmaceutical companies are also contributing to the growth of the market.
The Hepatitis C Drugs Market is segmented into direct-acting antivirals (DAAs) and interferon-based therapies. DAAs, which include drugs such as Sovaldi, Harvoni, and Epclusa, have revolutionized the treatment of Hepatitis C by offering high cure rates and shorter treatment duration. Interferon-based therapies, while still used in some cases, have largely been replaced by DAAs due to their lower cure rates and associated side effects.
Read More- https://cmi-latestreportorientedblogs.blogspot.com/2023/02/the-global-hepatitis-c-drugs-market.html
